应用ADC磁共振成像与机器学习识别儿童低级别神经上皮肿瘤的多分类分子亚型
这项回顾性双机构研究纳入儿童低级别神经上皮肿瘤患者,从ADC图提取影像组学特征并结合临床变量,用随机森林多分类预测KIAA1549-BRAF融合、BRAF V600E突变和非BRAF三类分子状态;影像组学联合临床特征的三分类平均测试AUC为0.77(95%CI 0.75-0.77),其中识别KIAA1549-BRAF融合的AUC为0.81。
要点
- ADC影像组学联合临床特征的三分类平均测试AUC为0.77(95%CI 0.75-0.77)。
- 识别KIAA1549-BRAF融合的AUC为0.81,高于BRAF V600E突变(0.75)和非BRAF(0.74)。
- 仅影像组学特征的平均测试AUC为0.74(95%CI 0.73-0.75),仅临床特征为0.67(95%CI 0.66-0.68)。
核心结论
- 肿瘤分割区的ADC值具有可用于训练机器学习分类器识别PLGNT分子生物标志物的鉴别信号。
研究设计与样本
- 回顾性双机构研究,搜索PACS获取儿童PLGNT基线脑MRI;第一家机构299例、第二家机构23例;使用3D Slicer半自动水平追踪效应工具在ADC图上进行半自动肿瘤分割;从病历回顾收集年龄、性别和肿瘤位置;肿瘤分子状态来自活检;采用多分类随机森林预测分子状态,并在验证集上通过网格搜索微调;基于合并数据的独立且未见测试集评估模型,计算三类预测的AUC;使用不同随机数据划分和模型初始化重复实验100次。
诊断标准与关键数值
- 三类预测对象为KIAA1549-BRAF融合、BRAF V600E突变和非BRAF队列;仅影像组学特征的平均测试AUC为0.74(95%CI 0.73-0.75);仅临床特征的平均测试AUC为0.67(95%CI 0.66-0.68);影像组学与临床特征联合的平均测试AUC为0.77(95%CI 0.75-0.77);联合特征识别KIAA1549-BRAF融合的AUC为0.81,BRAF V600E突变为0.75,非BRAF为0.74。
临床应用与阅片要点
- 作者认为,基于ADC的PLGNT治疗前BRAF状态鉴别有潜力避免有创肿瘤活检并使得靶向治疗能够更早启动。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Molecular biomarker identification increasingly influences the treatment planning of pediatric low-grade neuroepithelial tumors (PLGNTs). We aimed to develop and validate a radiomics-based ADC signature predictive of the molecular status of PLGNTs.
MATERIALS AND METHODS: In this retrospective bi-institutional study, we searched the PACS for baseline brain MRIs from children with PLGNTs. Semiautomated tumor segmentation on ADC maps was performed using the semiautomated level tracing effect tool with 3D Slicer. Clinical variables, including age, sex, and tumor location, were collected from chart review. The molecular status of tumors was derived from biopsy. Multiclass random forests were used to predict the molecular status and fine-tuned using a grid search on the validation sets. Models were evaluated using independent and unseen test sets based on the combined data, and the area under the receiver operating characteristic curve (AUC) was calculated for the prediction of 3 classes: KIAA1549-BRAF fusion, BRAF V600E mutation, and non-BRAF cohorts. Experiments were repeated 100 times using different random data splits and model initializations to ensure reproducible results.
RESULTS: Two hundred ninety-nine children from the first institution and 23 children from the second institution were included (53.6% male; mean, age 8.01 years; 51.8% supratentorial; 52.2% with KIAA1549-BRAF fusion). For the 3-class prediction using radiomics features only, the average test AUC was 0.74 (95% CI, 0.73-0.75), and using clinical features only, the average test AUC was 0.67 (95% CI, 0.66-0.68). The combination of both radiomics and clinical features improved the AUC to 0.77 (95% CI, 0.75-0.77). The diagnostic performance of the per-class test AUC was higher in identifying KIAA1549-BRAF fusion tumors among the other subgroups (AUC = 0.81 for the combined radiomics and clinical features versus 0.75 and 0.74 for BRAF V600E mutation and non-BRAF, respectively).
CONCLUSIONS: ADC values of tumor segmentations have differentiative signals that can be used for training machine learning classifiers for molecular biomarker identification of PLGNTs. ADC-based pretherapeutic differentiation of the BRAF status of PLGNTs has the potential to avoid invasive tumor biopsy and enable earlier initiation of targeted therapy.
引用
- Soldatelli MD, Namdar K, Tabori U, et al. Identification of Multiclass Pediatric Low-Grade Neuroepithelial Tumor Molecular Subtype with ADC MR Imaging and Machine Learning. AJNR Am J Neuroradiol. 2024. PMID: 38604736. doi:10.3174/ajnr.A8199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。